Brandi Simpson, MBA, Chief Business Officer

Brandi is Chief Business Officer of Navigen. She has held positions in business development, corporate strategy, and investor relations at NPS Pharmaceuticals.  At NPS, Brandi negotiated and closed an out-licensing agreement worth over $90 million for the European rights to NPS’s lead product, PREOS; rights to early stage series of compounds for treatment of Alzheimer’s disease; and rights to drug delivery formulations.  Prior to joining NPS, she was director of business development at Emergen, a Utah genetics start-up.  Brandi was a life sciences management consultant at Booz Allen & Hamilton where she advised clients on a variety of business and strategic issues including mergers and acquisitions, post-merger integration and development of new business ventures.  She began her career as an investment banking analyst at Merrill Lynch where she worked on multiple public debt and equity financing transactions, structured financings, and mergers and acquisitions. 

Brandi graduated summa cum laude from the University of Utah with an honors degree in Finance.  She earned an MBA degree at Stanford University’s Graduate School of Business.